IL161572A0 - Adenosine a2a receptor antagonists - Google Patents

Adenosine a2a receptor antagonists

Info

Publication number
IL161572A0
IL161572A0 IL16157202A IL16157202A IL161572A0 IL 161572 A0 IL161572 A0 IL 161572A0 IL 16157202 A IL16157202 A IL 16157202A IL 16157202 A IL16157202 A IL 16157202A IL 161572 A0 IL161572 A0 IL 161572A0
Authority
IL
Israel
Prior art keywords
adenosine
receptor antagonists
antagonists
receptor
Prior art date
Application number
IL16157202A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL161572A0 publication Critical patent/IL161572A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL16157202A 2001-11-30 2002-11-26 Adenosine a2a receptor antagonists IL161572A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33429301P 2001-11-30 2001-11-30
PCT/US2002/038134 WO2003048164A2 (en) 2001-11-30 2002-11-26 Adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
IL161572A0 true IL161572A0 (en) 2004-09-27

Family

ID=23306533

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16157202A IL161572A0 (en) 2001-11-30 2002-11-26 Adenosine a2a receptor antagonists

Country Status (19)

Country Link
US (1) US7041666B2 (hu)
EP (1) EP1453835B1 (hu)
JP (2) JP4284181B2 (hu)
KR (1) KR20050044607A (hu)
CN (1) CN1596258A (hu)
AR (1) AR038366A1 (hu)
AT (1) ATE317844T1 (hu)
AU (1) AU2002346572A1 (hu)
CA (1) CA2468681C (hu)
DE (1) DE60209251T2 (hu)
ES (1) ES2258164T3 (hu)
HK (1) HK1064100A1 (hu)
HU (1) HUP0402270A3 (hu)
IL (1) IL161572A0 (hu)
MX (1) MXPA04005156A (hu)
PE (1) PE20030739A1 (hu)
TW (1) TW200300686A (hu)
WO (1) WO2003048164A2 (hu)
ZA (1) ZA200404160B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058320A1 (en) * 2002-09-24 2006-03-16 Kyowa Hakko Kogyo Co., Ltd. [1,2,4] Triazolo[1,5-c]pyrimidine derivatives
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP2269596A3 (en) 2002-12-19 2011-09-14 Schering Corporation Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
CA2541989C (en) * 2003-10-24 2013-10-01 Exelixis, Inc. P70s6 kinase modulators and method of use
AR050926A1 (es) 2004-09-03 2006-12-06 Astrazeneca Ab Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac)
JPWO2006129626A1 (ja) * 2005-05-30 2009-01-08 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP2532658A1 (en) * 2007-05-24 2012-12-12 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for cerebral infarction
BRPI0813647A2 (pt) * 2007-06-25 2014-12-23 Neurogen Corp Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
US20100093764A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093756A1 (en) * 2008-10-13 2010-04-15 Berbay J Kent HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
CA2750783C (en) 2008-11-25 2015-10-13 Nissan Motor Co., Ltd. Electrical conductive member and polymer electrolyte fuel cell using the same
WO2010126811A1 (en) * 2009-04-27 2010-11-04 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
WO2011084985A1 (en) 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
WO2012038980A2 (en) * 2010-09-24 2012-03-29 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
ES2919474T3 (es) * 2017-04-07 2022-07-26 Medshine Discovery Inc Derivado de [1,2,4]triazolo[1,5-c]pirimidina como inhibidor del receptor A2A
IL303087B1 (en) * 2018-02-27 2024-08-01 Incyte Corp Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors
US11649239B2 (en) 2018-04-28 2023-05-16 Medshine Discovery Inc. Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
CN113166153A (zh) 2018-07-05 2021-07-23 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
AR116315A1 (es) 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
US20220040184A1 (en) * 2018-11-20 2022-02-10 Merck Sharp Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106558A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JP7241871B2 (ja) 2018-11-30 2023-03-17 メルク・シャープ・アンド・ドーム・エルエルシー アデノシン受容体拮抗薬としての９－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
US11459329B2 (en) 2018-12-20 2022-10-04 Incyte Corporation Imidazopyridazine and imidazopyridine compounds and uses thereof
WO2020128036A1 (en) * 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
US5565460A (en) 1993-07-27 1996-10-15 Kyowa Hakko Koygo Co., Ltd. Therapeutic purine agents for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
EP0976753B1 (en) 1997-03-24 2004-01-02 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
EP1116722B1 (en) 1998-09-22 2005-01-12 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
KR100520907B1 (ko) 2000-05-26 2005-10-11 쉐링 코포레이션 아데노신 Ａ2ａ수용체 길항제
JPWO2002079204A1 (ja) * 2001-03-28 2004-07-22 協和醗酵工業株式会社 ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
AU2002352933A1 (en) 2001-11-30 2003-06-17 Schering Corporation [1,2,4]-triazole bicylic adenosine A2a receptor antagonists

Also Published As

Publication number Publication date
ES2258164T3 (es) 2006-08-16
HUP0402270A2 (hu) 2005-02-28
US7041666B2 (en) 2006-05-09
JP2005511698A (ja) 2005-04-28
HK1064100A1 (en) 2005-01-21
WO2003048164A2 (en) 2003-06-12
DE60209251D1 (de) 2006-04-20
US20030212080A1 (en) 2003-11-13
ATE317844T1 (de) 2006-03-15
AU2002346572A1 (en) 2003-06-17
WO2003048164A3 (en) 2003-10-16
EP1453835A2 (en) 2004-09-08
DE60209251T2 (de) 2006-11-09
HUP0402270A3 (en) 2008-09-29
AR038366A1 (es) 2005-01-12
CA2468681C (en) 2011-01-25
MXPA04005156A (es) 2004-08-11
ZA200404160B (en) 2005-04-08
CA2468681A1 (en) 2003-06-12
JP2008303217A (ja) 2008-12-18
JP4284181B2 (ja) 2009-06-24
TW200300686A (en) 2003-06-16
EP1453835B1 (en) 2006-02-15
PE20030739A1 (es) 2003-08-28
CN1596258A (zh) 2005-03-16
KR20050044607A (ko) 2005-05-12

Similar Documents

Publication Publication Date Title
IL152726A0 (en) Adenosine a2a receptor antagonists
IL161572A0 (en) Adenosine a2a receptor antagonists
HUP0401925A3 (en) A2b adenosine receptor antagonists
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
IL175759A0 (en) A2b adenosine receptor antagonists
HUP0401437A3 (en) Adenosine a3 receptor agonists
HK1064097A1 (en) Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists
MXPA03004439A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina.
EP1636229A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
PL373953A1 (en) 7-amino-benzothiazole derivatives as adenosine receptor ligands
SI1622912T1 (sl) 2-alkinil- in 2-alkenil-pirazolo-(4,3-E)-1,2,4-triazolo-(1,5-C)-pirimidin adenozinski A2a receptorski antagonisti
HK1059927A1 (en) Condensed purine derivatives as a1 adenosine receptor antagonists
NO20020979D0 (no) Selektive A2B-adenosin reseptorantagonister
IL162444A0 (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
AU2002359524A8 (en) P2x7 receptor antagonists
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
GB0101223D0 (en) Histamine receptor antagonists
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
IL158063A0 (en) Crf receptor antagonists
SI1401837T1 (sl) Purinski derivati kot antagonisti adenozinskega receptorja A2B
AU2002320199A1 (en) Purine derivatives as a2b adenosine receptor antagonists
GB0125183D0 (en) Receptor
GB0114929D0 (en) Receptor
GB0110662D0 (en) Receptor
GB0111959D0 (en) Receptor